ATE473758T1 - Her-2/neu multipeptidimpfstoff - Google Patents

Her-2/neu multipeptidimpfstoff

Info

Publication number: ATE473758T1
Authority: AT; Austria
Prior art keywords: new; vaccine; multipeptide vaccine; multipeptide; neu
Prior art date: 2006-04-13

Application number

AT06007834T

Other languages

English (en)

Inventor

Christoph Zielinski

Otto Schreiner

Hubert Pehamberger

Heimo Breiteneder

Ursula Wiedermann

Original Assignee

Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-04-13

Filing date

2006-04-13

Publication date

2010-07-15

2006-04-13 Application filed by Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh filed Critical Bio Life Science Forschungs & Entwicklungsgesellschaft Mbh

2010-07-15 Application granted granted Critical

2010-07-15 Publication of ATE473758T1 publication Critical patent/ATE473758T1/de

Links

101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract 3
102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 3
229940035036 multi-peptide vaccine Drugs 0.000 title 1
229960005486 vaccine Drugs 0.000 abstract 2
108700020796 Oncogene Proteins 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
102000004196 processed proteins & peptides Human genes 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55538—IL-12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Oncology (AREA)
Cell Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT06007834T 2006-04-13 2006-04-13 Her-2/neu multipeptidimpfstoff ATE473758T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP06007834A EP1844788B1 (de)	2006-04-13	2006-04-13	HER-2/neu Multipeptidimpfstoff

Publications (1)

Publication Number	Publication Date
ATE473758T1 true ATE473758T1 (de)	2010-07-15

Family

ID=37110206

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06007834T ATE473758T1 (de)	2006-04-13	2006-04-13	Her-2/neu multipeptidimpfstoff

Country Status (9)

Country	Link
US (1)	US20090269364A1 (de)
EP (2)	EP1844788B1 (de)
AT (1)	ATE473758T1 (de)
AU (1)	AU2007237491B2 (de)
CA (1)	CA2649013C (de)
DE (1)	DE602006015421D1 (de)
ES (1)	ES2348312T3 (de)
IL (1)	IL194162A (de)
WO (1)	WO2007118660A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0724357D0 (en) *	2007-12-14	2008-01-23	Glaxosmithkline Biolog Sa	Method for preparing protein conjugates
JP2010006705A (ja) *	2008-06-13	2010-01-14	Atlas Antibodies Ab	Ｈｅｒ２サブセット
US9974844B2 (en) *	2008-11-17	2018-05-22	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
NZ598356A (en) *	2009-07-30	2014-06-27	Pfizer Vaccines Llc	Antigenic tau peptides and uses thereof
EP2292258A1 (de) *	2009-08-18	2011-03-09	Pevion Biotech Ltd.	Multiepitop-Impfstoff für Her2/neu-assoziierten Krebs
KR102274211B1 (ko) *	2011-11-23	2021-07-09	인3바이오 리미티드	재조합 단백질 및 그들의 치료적 용도
CA2863658C (en) *	2012-02-03	2023-03-14	Emory University	Immunostimulatory compositions, particles, and uses related thereto
TWI740823B (zh)	2015-04-17	2021-10-01	澳大利亞商保健樂科技昆士蘭有限公司	疫苗組成物及其用途
WO2016184862A1 (en) *	2015-05-18	2016-11-24	Oncoqr Ml Gmbh	Her2/neu immunogenic composition
WO2018145020A1 (en)	2017-02-03	2018-08-09	The Medical College Of Wisconsin, Inc.	Kras peptide vaccine compositions and method of use
EP3723792A2 (de)	2017-12-11	2020-10-21	Medizinische Universität Wien	Verfahren zur herstellung einer impfstoffzusammensetzung und deren verwendung
US12029783B2 (en)	2019-07-02	2024-07-09	Virago Vax Inc.	Mammary tumor virus vaccine
CA3145363A1 (en) *	2019-07-02	2021-01-07	Virago Vax Inc.	Mammary tumor virus vaccine
US12016844B2 (en)	2019-07-02	2024-06-25	Virago Vax Inc.	Mammary tumor virus suppression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH05117165A (ja) *	1991-10-24	1993-05-14	Masakazu Ueda	抗癌剤
US7060284B1 (en) *	1999-08-03	2006-06-13	The Ohio State University	Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
EP1236740B1 (de) *	2001-02-28	2012-07-18	Bio Life Science Forschungs- und Entwicklungsges.m.b.H.	Vakzine gegen Krebserkrankungen, die mit dem HER-2/neu Onkogen assoziiert sind
DK1390535T3 (da) *	2001-04-26	2010-12-06	Amgen Mountain View Inc	Kombinatoriske biblioteker af monomer-domæner

2006
- 2006-04-13 AT AT06007834T patent/ATE473758T1/de active
- 2006-04-13 EP EP06007834A patent/EP1844788B1/de not_active Expired - Lifetime
- 2006-04-13 ES ES06007834T patent/ES2348312T3/es not_active Expired - Lifetime
- 2006-04-13 DE DE602006015421T patent/DE602006015421D1/de not_active Expired - Lifetime
2007
- 2007-04-11 EP EP07724167A patent/EP2004218A2/de not_active Withdrawn
- 2007-04-11 AU AU2007237491A patent/AU2007237491B2/en active Active
- 2007-04-11 WO PCT/EP2007/003226 patent/WO2007118660A2/en not_active Ceased
- 2007-04-11 US US12/296,738 patent/US20090269364A1/en not_active Abandoned
- 2007-04-11 CA CA2649013A patent/CA2649013C/en active Active
2008
- 2008-09-17 IL IL194162A patent/IL194162A/en active IP Right Grant

Also Published As

Publication number	Publication date
IL194162A0 (en)	2011-08-01
WO2007118660A2 (en)	2007-10-25
EP1844788B1 (de)	2010-07-14
AU2007237491A1 (en)	2007-10-25
AU2007237491B2 (en)	2012-11-01
EP2004218A2 (de)	2008-12-24
CA2649013A1 (en)	2007-10-25
US20090269364A1 (en)	2009-10-29
IL194162A (en)	2014-04-30
WO2007118660A3 (en)	2007-12-13
EP1844788A1 (de)	2007-10-17
CA2649013C (en)	2017-05-02
ES2348312T3 (es)	2010-12-02
DE602006015421D1 (de)	2010-08-26

Legal Events

Date

Code

Title

Description

2011-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1844788

Country of ref document: EP

Publication	Publication Date	Title
IL194162A0 (en)	2011-08-01	Her-2/neu multi-peptide vaccine
PH12014501083A1 (en)	2014-08-04	Anticancer fusion protein
ATE387233T1 (de)	2008-03-15	Schutzhülse für nadeln mit absatz
PH12013500714A1 (en)	2013-06-10	Anticancer fusion protein
CL2009001258A1 (es)	2010-09-10	Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
WO2008046911A3 (en)	2008-07-03	Novel human micrornas associated with cancer
GT200600092A (es)	2006-10-02	Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
NZ611108A (en)	2015-10-30	Methods of treating fgf21-associated disorders
BRPI0807896A2 (pt)	2014-06-17	Fórceps bipolares não-aderentes.
EA200802170A1 (ru)	2009-06-30	Лиофилизированная композиция терапевтического пептидного антитела
EA201000327A1 (ru)	2010-10-29	Белок
BR112014019901A2 (pt)	2017-07-04	proteínas de fator viii recombinante
EA201000865A1 (ru)	2010-12-30	Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений
PL393578A1 (pl)	2012-07-16	Przeciwnowotworowe białko fuzyjne
CL2007003849A1 (es)	2008-07-04	Compuestos derivados de nafto[c]pirrol sustituidos con aminoacidos, utiles para tratar el cancer.
WO2008136869A3 (en)	2009-02-05	Methods and compositions related to targeting wounds, regenerating tissue, and tumors
NZ604089A (en)	2015-03-27	Multivalent glycopeptide constructs and uses thereof
WO2008153933A3 (en)	2017-02-02	Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
CY1116269T1 (el)	2017-02-08	Χρηση μιας πρωτεϊνης απο λουπινο
AR076892A1 (es)	2011-07-13	Conjugados de albumina-peptido amiloide y usos de los mismos
WO2009138494A3 (en)	2010-02-25	Amino acid sequences directed against toll-like receptors and their use for the treatment of diseases related to toll-like receptors
ATE538660T1 (de)	2012-01-15	Verfahren zur herstellung eines weizenproteinhydrolysats
PL394618A1 (pl)	2012-10-22	Przeciwnowotworowe bialko fuzyjne
WO2010052243A3 (en)	2010-08-19	Neurotensin-derived branched peptides and uses thereof
MX2010010177A (es)	2012-08-23	Fragmentos de beta timosina mejorada.